Guidelines for pre‐transfusion compatibility procedures in blood transfusion laboratories

1. INTRODUCTION1.1. Purpose of pre-transfusion guidelines.Technicalerrors and/or inappropriate test systems or administrativeerrors may result in immediate and delayed haemolytictransfusion reactions. The purpose of these guidelines,which replace those previously published (BCSH,1991a), is to define organizational, documentation andtechnical procedures undertaken in hospital or RegionalTransfusion Centre laboratories prior to blood transfu-sion.1.2. Elements in pre-transfusion testing1.2.1. ABO and RhD grouping of the recipient1.2.2. Antibody screen of the recipient, or mother in thecase of neonatal transfusion, which in the event of apositive screen, should be followed by antibody identi-fication.1.2.3. A computer or manual check of records. Thesethree elements constitute a group and screen.1.2.4. Donor red cell selection and crossmatching.1.2.5. In certain emergencies, the recipient’s need forimmediate red cell support may dictate that pre-transfu-sion testing is abbreviated.1.3. Clinical significance of red cell antibodies1.3.1. Clinically significant antibodies are those whichare capable of giving rise to accelerated destruction ofred cells bearing the relevant antigen.1.3.2. Anti-A, anti-B and anti-A,B must always beregarded to be of clinical significance.1.3.3. With few exceptions, irregular antibodies whichare potentially clinically significant are only those whichare reactive in the indirect antiglobulin test (IAT),performed strictly at 37

[1]  H. Oberman,et al.  Discrepancies in reverse ABO typing due to prozone , 1988, Transfusion.

[2]  J. Edwards,et al.  Chloroquine dissociation of antigen‐antibody complexes , 1982, Transfusion.

[3]  C. Mueller-Eckhardt,et al.  PLATELET ALLOANTIGENS‐MOLECULAR, GENETIC, AND CLINICAL ASPECTS , 1994, Vox sanguinis.

[4]  M. Scott,et al.  Review of the Problems Involved in Using Enzymes in Blood Group Serology ‐ Provision of Freeze‐Dried ICSH/ISBT Protease Enzyme and Anti‐D Reference Standards , 1994, Vox sanguinis.

[5]  P. Ness To match or not to match: the question for chronically transfused patients with sickle cell anemia , 1994, Transfusion.

[6]  D. Branch,et al.  A new reagent (ZZAP) having multiple applications in immunohematology. , 1982, American journal of clinical pathology.

[7]  D. Voak Validation of new technology for antibody detection by antiglobulin tests , 1992, Transfusion medicine.

[8]  P. Dendy,et al.  Guidelines on gamma irradiation of blood components for the prevention of transfusion‐associated graft‐versus‐host disease , 1996, Transfusion medicine.

[9]  C. Bebbington,et al.  BCSH‐NIBSC anti‐D reference reagent for antiglobulin tests: the in‐house assessment of red cell washing centrifuges and of operator variability in the detection of weak, macroscopic agglutination , 1993, Transfusion medicine.

[10]  J. Peristeri,et al.  Red Cell Alloantibodies in Patients with Thalassemia , 1990, Vox sanguinis.

[11]  C. Wardrop,et al.  Guidelines for administration of blood products: transfusion of infants and neonates , 1994, Transfusion medicine.

[12]  Marion L. Scott,et al.  Recommendations for evaluation, validation and implementation of new techniques for blood grouping, antibody screening and cross‐matching * , 1995, Transfusion medicine.

[13]  D. Dawson,et al.  Alloantibody responses in multiply transfused sickle cell patients. , 2008, Tissue antigens.

[14]  P. Mollison Blood transfusion in clinical medicine , 1967 .

[15]  K. Sazama,et al.  Reports of 355 transfusion‐associated deaths: 1976 through 1985 , 1990, Transfusion.

[16]  B. Moore,et al.  Replicate tests for the detection and correction of errors in anti-human globulin (AHG) tests: optimum conditions and quality control. , 1988, Haematologia.